Summit moderator Dennis Scanlon, PhD, asked the panelists to sum up their thoughts from the day’s discussions.
“At this point, the [Centers for Medicare & Medicaid Services] and the [Center for Medicare Innovation] in particular should ratchet back” their efforts, declares Francois de Brantes, executive director of the Healthcare Incentives Improvement Institute. He sees their efforts as too many fits and starts, and although they have moved the needle on reform, none of the individual initiatives can be rated “a stellar A.” Over the next 4 to 5 years, innovations in the private sector will serve as a primary engine and the federal government can learn what works with the models as they evolve, he adds. The delivery system can be fully transformed when other innovations emerge, and we will learn from that, predicts Mr de Brantes.
There is no final solution so far regarding healthcare costs, according to Arthur Vercillo, MD, FACS, regional president of Excellus Blue Cross Blue Shield, although the ACA has led to consumers having more skin in the game, which he believes will make a difference. However, the real game is to maintain or improve the quality of healthcare while holding down costs. “We know what the cost drivers are, and they need to be attacked individually,” he states.
Even though accessibility with the ACA is progressing, Dr Vercillo says we are not there yet, although over the next few years “We’ll be in a much better place when it comes to quality, cost and accessibility, and we need to.”
Ateev Mehrotra, MD, MPH, associate professor of healthcare policy and medicine at Harvard Medical School and a hospitalist at Beth Israel Deaconess Medical Center agrees with Mr de Brantes’ assessment of the ACA approach of trying different avenues to manage healthcare spending. He points to patient-centered medical homes, which sound rational in theory but have not had much of an impact. “We just can’t go based on theory anymore. We have to say, ‘Okay, the evidence is that a particular intervention didn’t work. Maybe ACOs did work. Let’s put more of our energy there.’” We must eliminate programs that are not working, he emphasizes.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Patients With RA in Remission Withdrawing From TNF Inhibition Show Flare Increases
December 8th 2023New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued a tumor necrosis factor inhibitor (TNFi).
Read More